The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
Open accessPublished version of a preprint
Abstract
Natural killer (NK) cells are immune cells sensing and eliminating foreign, stressed, transformed, and senescent cells through specialized surface receptors, such as NKG2D, that interacts with several virus- or stress-inducible ligands, including ULBP1 and -2, which are expressed on target cell surfaces. For example, induction of DNA damage or cellular senescence pathways in tumor cells led to upregulation of NKG2D ligands that activate NK cells. Although, both pathways activate p53, the relationship of p53 activation to upregulation of NKG2D ligands has not been addressed. In this study, we report that induction of wild-type p53, but not mutant p53, strongly upregulated mRNA and cell surface expression of ULBP1 and -2, whereas expression of other NK cell ligands was not affected. We defined intronic p53-responsive elements in these two novel p53 target genes. Coculture of wild-type p53-induced human tumor cells with primary human NK cells enhanced NKG2D-dependent degranulation and IFN-γ production by NK cells. Accordingly, treatment of certain wild-type p53-expressing tumor cell lines with the p53-reactivating small molecular compound RITA resulted in upregulation of ULBP2 mRNA and cell surface protein expression. Taken together, our findings define the involvement of p53 in the regulation of specific NKG2D ligands that enhance NK cell–mediated target recognition. One implication of our work is that activating p53 after adoptive transfer of NK cells might constitute an effective combinatorial strategy of NK cell–based immunochemotherapy in cancers in which wild-type p53 function is preserved. Cancer Res; 71(18); 5998–6009. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In brief, the status of genes can influence tumor cells not only through the impact of wild-type gene loss but also through their effects on the TIME.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“Some missense mutant proteins can lose the transcriptional effects of wild-type genes, such as keeping PDL1 expression levels low, thereby making cancer cells more susceptible to cytotoxic T cells and NK cells, limiting the immune system’s ability to attack cancer cells.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“On the other hand, activating wild-type proteins can increase IFNγ signaling and sensitize tumors to immune checkpoint inhibitors, whereas corresponding mutant proteins can reduce the efficacy of immune checkpoint inhibitors.612–614”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“In contrast, two studies reported that pharmacological reactivation of p53 in specific cell lines can stimulate the expression of ULPB2, a ligand for human NKG2D (Li et al., 2011; Textor et al., 2011).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Textor et al., 2011
In the citing paper
“Additional immunostimulatory effects linked to pharmacological p53 reactivation in cancer cells include (but are not limited to) (1) downregulation of immunomodulatory cytokines linked to tumor progression, such as IL6 (Sahin et al., 2020); (2) upregulation of NKALs (Textor et al., 2011); and (3) establishment of cellular senescence linked to an immunostimulatory SASP that favors the recruitment”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Textor et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Recently, it has been shown that reactivation of p53 in mouse cancer models induced rapid tumor regression by the induction of apoptosis or cellular senescence depending on the tumor type (5).”
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J. D., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,674
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W. A., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,394
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
Martin‐Fontecha, A., Thomsen, L. L., Brett, S. J., Gerard, C. J., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2004) · Nature Immunology · doi:10.1038/ni1138 · Cited by 1,351
Cited by
Sorted by citations
Items 101–200 of 221
Epigenetic Regulation of Cancer Immune Cells
Patino, D. M. A., Radhakrishnan, V., Suvilesh, K. N., Manjunath, Y., Li, G., Kimchi, E. T., Staveley-O’Carroll, K. F., Warren, W. C., Kaifi, J. T., & Mitchem, J. B. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.022 · Cited by 26
Unleashing the power of NK cells in anticancer immunotherapy
Vogler, M., Shanmugalingam, S., Särchen, V., Reindl, L. M., Grèze, V., Buchinger, L., Kühn, M. W. M., & Ullrich, E. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02120-z · Cited by 28
The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?
Yin, T., Xin, H., Yu, J., & Teng, F. (2021) · Biomarker Research · doi:10.1186/s40364-021-00277-w · Cited by 25
Engineered Three-Dimensional Tumor Models to Study Natural Killer Cell Suppression
Temples, M. N., Adjei, I. M., Nimocks, P. M., Djeu, J. Y., & Sharma, B. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00259 · Cited by 24
Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents
Carlsen, L., & El‐Deiry, W. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111828 · Cited by 27
Adjei, I. M., Jordan, J. C., Tu, N., Trinh, T. L., Kandell, W. M., Wei, S., & Sharma, B. (2019) · Journal of Interdisciplinary Nanomedicine · doi:10.1002/jin2.63 · Cited by 24
Targeting NKG2D in tumor surveillance
Hayakawa, Y. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.681378 · Cited by 24
Vineretsky, K. A., Karagas, M. R., Christensen, B. C., Kuriger, J. K., Perry, A. E., Storm, C. A., & Nelson, H. H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0547 · Cited by 23
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
Tamura, R. E., Soares, R. B. D. S., Costanzi-Strauss, E., & Strauss, B. E. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235655 · Cited by 22
Lu, H., Ma, Y., Wang, M., Shen, J., Wu, H., Li, J., Gao, N., Gu, Y., Zhang, X., Zhang, G., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02771-w · Cited by 22
TP53 Deficiency in the Natural History of Prostate Cancer
Ofner, H., Kramer, G., Shariat, S. F., & Hassler, M. R. (2025) · Cancers · doi:10.3390/cancers17040645 · Cited by 23
Liu, M., Du, M., Yu, J., Qian, Z., Gao, Y., Pan, W., Zhao, X., Wang, M., Li, H., Zheng, J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2016158 · Cited by 20
Zhao, P., Sun, X., Li, H., Liu, Y., Cui, Y., Tian, L., & Cheng, Y. (2022) · Cancers · doi:10.3390/cancers14030457 · Cited by 21
Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer
Cai, J., Liu, W., Wong, C.-W., Zhu, W., Lin, Y., Hu, J. X., Xu, W., Zhang, J., Sander, M., Wang, Z., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01416-7 · Cited by 19
Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response
Baugh, R. T., Khalique, H., & Seymour, L. W. (2020) · Cancers · doi:10.3390/cancers12123827 · Cited by 23
Singh, D., Khan, M. A., & Siddique, H. R. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.04.003 · Cited by 20
A short half‐life of ULBP1 at the cell surface due to internalization and proteosomal degradation
Fernández‐Messina, L., Reyburn, H. T., & Valés‐Gómez, M. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.2 · Cited by 21
Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
Kwok, M., Agathanggelou, A., Davies, N., & Stanković, T. (2021) · Cancers · doi:10.3390/cancers13184681 · Cited by 20
Tumor-derived CSF-1 induces the NKG2D ligand RAE-1δ on tumor-infiltrating macrophages
Thompson, T. W., Jackson, B. T., Li, P. J., Wang, J., Kim, A. B., Huang, K. T. H., Zhang, L., & Raulet, D. H. (2018) · eLife · doi:10.7554/elife.32919 · Cited by 19
Elias, S., & Mandelboim, O. (2012) · RNA Biology · doi:10.4161/rna.19717 · Cited by 19
Zecher, B. F., Ellinghaus, D., Schloer, S., Niehrs, A., Padoan, B., Baumdick, M. E., Yuki, Y., Martin, M. P., Głów, D., Schröder‐Schwarz, J., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-329524 · Cited by 21
Effect ofEx VivoCulture Conditions on Immunosuppression by Human Mesenchymal Stem Cells
Lee, M. W., Kim, D. S., Ryu, S., Jang, I. K., Kim, H. J., Yang, J. M., Lee, D., Lee, S. H., Son, M. H., Cheuh, H. W., et al. (2013) · BioMed Research International · doi:10.1155/2013/154919 · Cited by 18
Immunosurveillance of cancer cell stress
Lorenzo‐Herrero, S., Sordo‐Bahamonde, C., Gonzalez, S. R., & López‐Soto, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.198 · Cited by 18
Zhang, S., Zhang, W., & Zhang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.938611 · Cited by 17
Veneziani, I., Fruci, D., Compagnone, M., Pistoia, V., Rossi, P., & Cifaldi, L. (2019) · Oncotarget · doi:10.18632/oncotarget.26736 · Cited by 17
The head and neck cancer genome in the era of immunotherapy
Wijetunga, N. A., Yu, Y., Morris, L. G. T., Lee, N. Y., & Riaz, N. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105040 · Cited by 17
Ray, A., Somanchi, S. S., Dastgheyb, N., Aquino‐López, A., Cobanoglu, Z. E., Geier, B., & Lee, D. A. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27783 · Cited by 16
Uddin, M. B., Roy, K. R., Hill, R. A., Roy, S. C., Gu, X., Li, L., Zhang, Q.-J., You, Z., & Liu, Y. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113210 · Cited by 16
The Modulation of the Cell-Cycle: A Sentinel to Alert the NK Cells of Dangers
Baychelier, F., & Vieillard, V. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00325 · Cited by 16
Uhlenbrock, F., Hagemann-Jensen, M., Kehlet, S. N., Andresen, L. O., Pastoreková, S., & Skov, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303275 · Cited by 16
The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications
Liang, L., & Wang, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1753215 · Cited by 16
Research progress on the multi-omics and survival status of circulating tumor cells
Xie, Q., Liu, S., Zhang, S., Liao, L., Xiao, Z., Wang, S., & Zhang, P. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01309-z · Cited by 15
Huang, S., Qin, Z.-H., Wang, F.-Y., Kang, Y.-X., & Ren, B. (2024) · Oncology Report · doi:10.3892/or.2024.8796 · Cited by 18
Metal-Based Anticancer Complexes and p53: How Much Do We Know?
Alfadul, S. M., Matnurov, E. M., Varakutin, A. E., & Babak, M. V. (2023) · Cancers · doi:10.3390/cancers15102834 · Cited by 15
Ingelshed, K., Melssen, M. M., Kannan, P., Chandramohan, A., Partridge, A. W., Jiang, L., Wermeling, F., Lane, D. P., Nestor, M., & Spiegelberg, D. (2024) · iScience · doi:10.1016/j.isci.2024.109862 · Cited by 15
The innate defenders: a review of natural killer cell immunotherapies in cancer
Álvarez-Carrasco, P., & Maldonado‐Bernal, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1482807 · Cited by 15
Choi, S. H., Jung, D., Kim, K. Y., An, H. J., & Park, K. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.066 · Cited by 14
Expression and prognostic significance of unique ULBPs in pancreatic cancer
Chen, J., Zhu, X., Xu, H., Fang, H.-Z., & Zhao, J.-Q. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s107771 · Cited by 14
Gallid Herpesvirus 1 Initiates Apoptosis in Uninfected Cells through Paracrine Repression of p53
Li, H., Gao, Q., Shao, Y., Sun, B., Wang, F., Qiao, Y., Wang, N., & Liu, S. (2018) · Journal of Virology · doi:10.1128/jvi.00529-18 · Cited by 14
Boutet, M., Nishitani, K., Couturier, N., Erler, P., Zhang, Z., Militello, A. M., de Miranda, M. C., Barbieux, E., Guillen, E., Leavenworth, J. W., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.008 · Cited by 12
Flip‐flops of natural killer cells in autoimmune diseases versus cancers: Immunologic axis
Shahrabi, S., Zayeri, Z. D., Ansari, N., Hadad, E. H., & Rajaei, E. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28421 · Cited by 11
Medrano, R. F. V., Hunger, A., Catani, J. P. P., & Strauss, B. E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1329072 · Cited by 11
Master regulator: p53’s pivotal role in steering NK-cell tumor patrol
Wang, H., Chen, Q., Liu, Q., & Luo, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428653 · Cited by 11
Diagnosis of Early-Stage Non-Small Cell Lung Cancer Using DNA Methylation in Tissue and Plasma
Li, L., Fu, K., Cai, X., Liu, D., Zhu, Y., Wang, W., Tian, P., Wang, Y., Xue, H., Snyder, M. P., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2025.101548 · Cited by 10
A novel facet of tumor suppression by p53
Li, H., Lakshmikanth, T., Carbone, E., & Selivanova, G. (2012) · OncoImmunology · doi:10.4161/onci.19409 · Cited by 10
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
Daifuku, R., Grimes, S. D., & Stackhouse, M. A. (2018) · Pharmaceuticals · doi:10.3390/ph11020036 · Cited by 12
TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC
Kong, W., Han, Y., Gu, H., Yang, H., & Zang, Y. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101359 · Cited by 10
Jensen, H., Hagemann-Jensen, M., Lauridsen, F. K. B., & Skov, S. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.08.011 · Cited by 10
Alves, E., McLeish, E., Blancafort, P., Coudert, J. D., & Gaudieri, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.712722 · Cited by 10
Berhani, O., Nachmani, D., Yamin, R., Schmiedel, D., Bar‐On, Y., & Mandelboim, O. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601589 · Cited by 9
Veneziani, I., Brandetti, E., Ognibene, M., Pezzolo, A., Pistoia, V., & Cifaldi, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/4972410 · Cited by 9
Brandetti, E., Focaccetti, C., Pezzolo, A., Ognibene, M., Folgiero, V., Cotugno, N., Benvenuto, M., Palma, P., Manzari, V., Rossi, P., et al. (2021) · Cancers · doi:10.3390/cancers13174368 · Cited by 9
Omidvar, S., Vahedian, V., Sourani, Z., Yari, D., Asadi, M., Jafari, N., Khodavirdilou, L., Bagherieh, M., Shirzad, M., & Hosseini, V. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155405 · Cited by 9
Human innate immune cell crosstalk induces melanoma cell senescence
Funck, F., Pahl, J. H. W., Kyjacová, L., Freund, L., Oehrl, S., Gräbe, G., Pezer, S., Hassel, J. C., Sleeman, J. P., Cerwenka, A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1808424 · Cited by 9
Self-citationCharacterization of 5′ promoter and exon 1–3 polymorphism of the RAET1E gene
Cox, S. T., Pearson, H. M., Briviesca, R. L., Pesoa, S., Vullo, C., Madrigal, J. A., & Saudemont, A. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.10.017 · Cited by 8
The ISG15-Protease USP18 Is a Pleiotropic Enhancer of HIV-1 Replication
Lin, C., Kuffour, E. O., Li, T., Gertzen, C. G. W., Kaiser, J., Luedde, T., König, R., Gohlke, H., & Münk, C. (2024) · Viruses · doi:10.3390/v16040485 · Cited by 7
Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D
Heinemann, A., & Paschen, A. (2012) · OncoImmunology · doi:10.4161/onci.19406 · Cited by 7
TP53: Coordinator of the Processes That Underlie the Hallmarks of Cancer
Hainaut, P. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_1 · Cited by 10
Chen, L., Lin, J., Wen, Y., Guo, Z., Lan, B., Xiong, J., Chen, C., & Chen, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s497295 · Cited by 6
Rewiring melanoma cell fate: TRPM8 modulators trigger apoptosis and boost NK cell cytotoxicity
Sorrentino, C., Lauretta, C., D’Angiolo, R., Musella, S., Giovannelli, P., Bertamino, A., Ostacolo, C., Monterrey, I. G., Migliaccio, A., Castoria, G., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08469-8 · Cited by 6
Pesini, C., Artal, L., Bernal, J. P., Sánchez‐Martínez, D., Pardo, J., & Ramírez-Labrada, A. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2379062 · Cited by 6
Ning, G., Li, Y., Chen, W., Tang, W., Shou, D., Luo, Q., Chen, H., & Zhou, Y. (2021) · Journal of Oncology · doi:10.1155/2021/2715694 · Cited by 6
Chen, Z., Cui, L., Xu, L. M., Liu, Z., Liang, Y., Li, X., Zhang, Y., Li, Y., Liu, S., & Li, H. (2022) · Poultry Science · doi:10.1016/j.psj.2022.102164 · Cited by 5
Emerging Role of the p53 Pathway in Modulating NK Cell–Mediated Immunity
Chen, Y., Bazewicz, C. G., Dinavahi, S. S., Huntington, N. D., Schell, T. D., & Robertson, G. P. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0325 · Cited by 6
Breast Cancer Immunity: It is TIME for the Next ChapterPreprint
Quail, D. F., Park, M., Welm, A. L., & Ekiz, H. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041324 · Cited by 6
Ashique, S., Debnath, B., Ramzan, M., Taj, T., Islam, A., Chaudhary, P., Kaushik, M., Garg, A., Sen, A., Raveendran, C., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118308 · Cited by 5
p53: An Immune Ecosystem Manipulator
Nian, Z., Dou, Y., & Wei, H. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3628 · Cited by 4
From Genome Guardian to Immune Modulator: The Expanding Roles of Tumor Suppressor p53
Wang, W., Liu, J., Feng, Z., & Hu, W. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2571187 · Cited by 4
Couture, C., Caron, M., St-Onge, P., Brien, M., Sinnett, D., Soglio, D. B. D., & Girard, S. (2024) · Placenta · doi:10.1016/j.placenta.2024.07.008 · Cited by 4
Li, X., Meng, W., Wang, X., Huang, S., Wang, J., Han, L., & Si, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1560706 · Cited by 4
Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers
Ma, J., Yue, J., Li, Y., Li, Y., Dong, H., Fang, F., & Xiao, W. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01113-1 · Cited by 3
The Immune Interplay between Thyroid Papillary Carcinoma and Hepatic Fibrosis
Muhanna, N., Amer, J., Salhab, A., Sichel, J., & Safadi, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132463 · Cited by 3
The Molecular Basis of the Immune Response to Stressed Cells and Tissues
Gonzalez, S. R., López‐Larrea, C., & López‐Soto, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801968-9.00003-9 · Cited by 3
UBC4: A Repurposed Drug Regimen for Adjunctive Use During Bladder Cancer Treatment
Kast, R. E. (2025) · Biomedicines · doi:10.3390/biomedicines13030706 · Cited by 2
A pyroptosis gene-based prognostic model for predicting survival in low-grade glioma
Wang, H., Lin, Y., Liu, L., Lu, X., Chen, Y., Zhang, Q., Chen, M., Cai, L., & Dai, Z. (2023) · PeerJ · doi:10.7717/peerj.16412 · Cited by 2
Senotherapy: Implications for Transplantation
Jaros, M., & Melk, A. (2025) · Transplantation · doi:10.1097/tp.0000000000005291 · Cited by 2
Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53
Wang, Z., Shi, M., Liu, B., Zhang, X., Lin, W., Yang, Y., Huang, Z., Yang, D., Chu, T., Zheng, D., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1492305 · Cited by 2
Cellular Immunotherapy—Highlights from TCT 2021
Reshef, R., Muranski, P. J., & Miller, J. S. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.04.015 · Cited by 2
UL16‑binding protein 1 is a significant prognostic and diagnostic marker for breast cancer
Zhang, X., Dai, S., Li, L., Wang, P., & Dong, M. (2024) · Oncology Letters · doi:10.3892/ol.2024.14761 · Cited by 1
Alves-Paiva, R. D. M., Coa, L. L., de Azevedo, J. T. C., da Silva, J. R., de Godoy, J. A. P., Sielski, M. S., Zanetti, L. C., Oliveira, D., Okamoto, O. K., Kutner, J. M., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102079 · Cited by 1
Będzińska, A., Gdowicz‐Kłosok, A., Krześniak, M., Łasut-Szyszka, B., Zeman, M., Chwieduk, A., Smagur, A., Jabłońska, J., & Rusin, M. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02772-9 · Cited by 1
Tang, K. (2012) · InTech eBooks · doi:10.5772/35177 · Cited by 1
Cytotoxicity of natural killer cells on canine mammary carcinoma cells
Jeong, D.-U., Byeon, J. S., Gu, N., Jung, M., Kim, E. H., Kim, H.-S., Cho, I., Song, J., Hyun, B., & Lee, J. (2020) · Korean Journal of Veterinary Research · doi:10.14405/kjvr.2020.60.1.25 · Cited by 1
Puzzling Regulation of Interferon Signaling System by p53 Tumor Suppressor ProteinPreprint
Będzińska, A., Łasut-Szyszka, B., Krześniak, M., Gdowicz‐Kłosok, A., & Rusin, M. (2024) · Preprints.org · doi:10.20944/preprints202404.1169.v1 · Cited by 1
Terapia gênica do câncer associando reparo da via p53 à imunoestimulação por IFNbeta
Catani, J. P. P. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2014.tde-26112014-100519 · Cited by 2
Tumor associated antigens and its potential use in cancer therapy
Sarmiento-Rubiano, L. A. (2015) · Salud Uninorte · doi:10.14482/sun.31.1.5981
Modulation of p53's transcriptional function by small molecules
Nikulenkov, F. (2011) · Figshare
Tumor-Produced Immune Regulating Factors
Andersen, M. H., Becker, J. C., & Straten, P. T. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_11
The Therapeutic Role of NK Cells in DC Immunotherapy
Caldwell, F. J. (2013) · Otago University Research Archive (University of Otago)
Unhealthy Nutrigenomic Diets Accelerate NAFLD and Adiposity in Global
Martins, I. J. (2015)
CellsSurveillance of Unhealthy Cells by Natural Killer
Iannello, A., & Raulet, D. H. (2013)
OPINION Interactions between the tumor suppressor p53 and immune responses
Menéndez, D., Shatz, M., & Resnick, M. A. (2013)
Diagnostic significance of serum cholinesterase and lactate dehydrogenase in skin malignancy.
Khan, N. A., Tyagi, S. P., & Salahuddin, A. (1987) · PubMed
Medrano, R. F. V. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-06042018-122815
Bermeister, K. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/508903
Role of γδ T Lymphocytes in Cancer Immunosurveillance and Immunotherapy
Lança, T., Correia, D. V., & Silva‐Santos, B. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_13
Metadata
- Authors
- Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Corresponding author
- Cerwenka, Adelheid
- Venue
- Cancer Research
- Published
- 2011-09-13
- Volume
- 71
- Issue
- 18
- Pages
- 5998-6009
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2123143632
- Cited by
- 221
- References
- 36
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 13 · 2022: 18 · 2021: 13 · 2020: 19 · 2019: 11 · 2018: 12 · 2017: 10 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 20 · 2012: 13
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- natural killer cells, NKG2D ligands, ULBP1, ULBP2, p53, wild-type p53, p53 target genes, p53 response elements, NK cell cytotoxicity, interferon-gamma, RITA, p53 reactivation
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Furans, Humans, Introns, Killer Cells, Natural, Lung Neoplasms, RNA, Messenger, Up-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, NK Cell Lectin-Like Receptor Subfamily K, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
